Virginia Retirement Systems ET AL lowered its holdings in Celgene Co. (NASDAQ:CELG) by 15.2% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 167,800 shares of the biopharmaceutical company’s stock after selling 30,000 shares during the quarter. Virginia Retirement Systems ET AL’s holdings in Celgene were worth $15,511,000 as of its most recent SEC filing.
Other large investors have also bought and sold shares of the company. Archford Capital Strategies LLC raised its position in Celgene by 277.8% in the first quarter. Archford Capital Strategies LLC now owns 272 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 200 shares during the period. Investors Research Corp acquired a new stake in shares of Celgene in the first quarter valued at $28,000. Weaver Consulting Group acquired a new stake in shares of Celgene in the first quarter valued at $29,000. Alera Investment Advisors LLC grew its stake in shares of Celgene by 109.9% in the first quarter. Alera Investment Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 167 shares in the last quarter. Finally, Mizuho Securities Co. Ltd. acquired a new stake in shares of Celgene in the first quarter valued at $31,000. Institutional investors own 74.77% of the company’s stock.
A number of equities research analysts have recently weighed in on CELG shares. Barclays cut Celgene from an “overweight” rating to an “equal weight” rating and set a $102.00 price objective for the company. in a research note on Friday, May 3rd. BidaskClub raised Celgene from a “strong sell” rating to a “sell” rating in a research note on Saturday. Mizuho reaffirmed a “buy” rating and issued a $103.00 price objective on shares of Celgene in a research note on Wednesday, July 3rd. Cowen reaffirmed a “hold” rating and issued a $102.00 price objective on shares of Celgene in a research note on Tuesday, July 30th. Finally, Zacks Investment Research raised Celgene from a “sell” rating to a “hold” rating and set a $94.00 price objective for the company in a research note on Tuesday, July 23rd. Two analysts have rated the stock with a sell rating, sixteen have issued a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $94.81.
Celgene (NASDAQ:CELG) last released its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $2.61 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.44 by $0.17. Celgene had a return on equity of 89.93% and a net margin of 32.24%. The firm had revenue of $4.40 billion during the quarter, compared to analysts’ expectations of $4.22 billion. During the same period in the previous year, the firm posted $2.16 EPS. Celgene’s revenue for the quarter was up 15.4% on a year-over-year basis. Research analysts forecast that Celgene Co. will post 9.96 earnings per share for the current fiscal year.
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.